Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Basic) (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EPS (Basic) for 8 consecutive years, with -$0.26 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 43.48% to -$0.26 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.14, a 106.14% increase, with the full-year FY2024 number at -$2.36, up 3.28% from a year prior.
  • EPS (Basic) was -$0.26 for Q3 2025 at Whitehawk Therapeutics, up from -$0.76 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $6.96 in Q4 2021 to a low of -$17.81 in Q3 2021.
  • A 5-year average of -$1.07 and a median of -$0.61 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 2050.0% in 2021, then soared 370.59% in 2025.
  • Whitehawk Therapeutics' EPS (Basic) stood at $6.96 in 2021, then plummeted by 106.9% to -$0.48 in 2022, then dropped by 25.0% to -$0.6 in 2023, then decreased by 13.33% to -$0.68 in 2024, then skyrocketed by 61.76% to -$0.26 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EPS (Basic) are -$0.26 (Q3 2025), -$0.76 (Q2 2025), and $1.84 (Q1 2025).